Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Consultas o comentarios: productividad@anid.cl
ISPAD Clinical Practice Consensus Guidelines 2018: Diabetes technologies
| Indexado |
|
||||
| DOI | 10.1111/PEDI.12731 | ||||
| Año | 2018 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Sherr, Jennifer L. | Mujer |
YALE UNIV - Estados Unidos
Yale School of Medicine - Estados Unidos |
| 2 | Tauschmann, Martin | Hombre |
UNIV CAMBRIDGE - Reino Unido
University of Cambridge - Reino Unido |
| 3 | Battelino, Tadej | Hombre |
UMC Univ Childrens Hosp - Eslovenia
Univ Ljubljana - Eslovenia University Children's Hospital, Ljubljana - Eslovenia University of Ljubljana Faculty of Medicine - Eslovenia Univerza v Ljubljani - Eslovenia |
| 4 | de Bock, Martin | Hombre |
UNIV OTAGO - Nueva Zelanda
University of Otago - Nueva Zelanda University of Otago, Christchurch - Nueva Zelanda |
| 5 | Forlenza, Gregory | Hombre |
Univ Colorado Denver - Estados Unidos
University of Colorado Health Sciences Center - Estados Unidos University of Colorado Anschutz Medical Campus - Estados Unidos |
| 6 | ROMAN-REYES, ROSSANA PATRICIA | Mujer |
Universidad de Antofagasta - Chile
Hospital Regional de Antofagasta - Chile |
| 7 | Hood, Korey K. | Hombre |
Universidad de Stanford - Estados Unidos
Stanford University School of Medicine - Estados Unidos |
| 8 | Maahs, David M. | Hombre |
Universidad de Stanford - Estados Unidos
Stanford University School of Medicine - Estados Unidos |
| Fuente |
|---|
| National Science Foundation |
| NIH |
| National Institutes of Health |
| NSF |
| Juvenile Diabetes Research Foundation United States of America |
| Medtronic |
| Sanofi |
| Abbott Laboratories |
| JDRF |
| Novo Nordisk |
| National Institute of Diabetes and Digestive and Kidney Diseases |
| Abbott |
| Roche |
| Sandoz |
| Dexcom |
| Tandem |
| Insulet |
| Diamyd |
| Bigfoot Biomedical |
| GluSense |
| Diamyd |
| Tandem |
| NovoNordisk |
| Dexcom, Inc. |
| NIH NIDDK |
| Dexcom |
| Bigfoot Biomedical |
| Insulet |
| GluSense |
| Helmsley Charitable Trust |
| Leona M. and Harry B. Helmsley Charitable Trust |
| Sandoz and Diamyd |
| Agradecimiento |
|---|
| J.L.S. reports having receiving speaker honoraria from Medtronic. J.L.S. also serves on advisory boards of Bigfoot Biomedical, Eli Lilly (Nasal Glucagon), and Insulet Corporation. J.L.S.'s institution received research grant support from JDRF, Medtronic and Insulet. M.T. reports having received speaker honoraria from Medtronic and Novo Nordisk. T.B. served on advisory boards of Novo Nordisk, Sanofi, Eli Lilly, Boehringer, Medtronic, DreaMed Diabetes and Bayer Health Care. T.B.'s Institution received research grant support, with receipt of travel and accommodation expenses in some cases, from Abbott, Medtronic, Novo Nordisk, GluSense, Sanofi, Sandoz and Diamyd. T.B. received honoraria for participating on the speaker's bureaux of Eli Lilly, Bayer, Novo Nordisk, Medtronic, Sanofi and Roche. T.B. owns stocks of DreamMed. M.D. has received honorarium from Medtronic. G.F. reports grants from NIH NIDDK; grants and personal fees from Medtronic, grants and personal fees from Tandem, grants and personal fees from Dexcom, grants from Insulet, grants and personal fees from Abbott, grants from Bigfoot, and grants from NovoNordisk. R.R. reports no conflicts of interest. K.H. serves as a consultant to J&J Diabetes Institute, Bigfoot Biomedical, Lilly Innovation Center, and Insulet. Receives research support for investigator-initiated study from Dexcom, Inc. D.M. has research support from the NIH, JDRF, NSF, and the Helmsley Charitable Trust and his institution has research support from Medtronic, Dexcom, Insulet, Bigfoot Biomedical, and Roche. D.M. has consulted for Abbott, the Helmsley Charitable Trust, Sanofi, and Eli Lilly and has served on an advisory board for Insulet. |
| J.L.S. reports having receiving speaker honoraria from Medtronic. J.L.S. also serves on advisory boards of Bigfoot Biomedical, Eli Lilly (Nasal Glucagon), and Insulet Corporation. J.L.S.'s institution received research grant support from JDRF, Medtronic and Insulet. M.T. reports having received speaker honoraria from Medtronic and Novo Nordisk. T.B. served on advisory boards of Novo Nordisk, Sanofi, Eli Lilly, Boehringer, Medtronic, DreaMed Diabetes and Bayer Health Care. T.B.'s Institution received research grant support, with receipt of travel and accommodation expenses in some cases, from Abbott, Medtronic, Novo Nordisk, GluSense, Sanofi, Sandoz and Diamyd. T.B. received honoraria for participating on the speaker's bureaux of Eli Lilly, Bayer, Novo Nordisk, Medtronic, Sanofi and Roche. T.B. owns stocks of DreamMed. M.D. has received honorarium from Medtronic. G.F. reports grants from NIH NIDDK; grants and personal fees from Medtronic, grants and personal fees from Tandem, grants and personal fees from Dexcom, grants from Insulet, grants and personal fees from Abbott, grants from Bigfoot, and grants from NovoNordisk. R.R. reports no conflicts of interest. K.H. serves as a consultant to J&J Diabetes Institute, Bigfoot Biomedical, Lilly Innovation Center, and Insulet. Receives research support for investigator-initiated study from Dexcom, Inc. D.M. has research support from the NIH, JDRF, NSF, and the Helmsley Charitable Trust and his institution has research support from Medtronic, Dexcom, Insulet, Bigfoot Biomedical, and Roche. D.M. has consulted for Abbott, the Helmsley Charitable Trust, Sanofi, and Eli Lilly and has served on an advisory board for Insulet. |
